1. Data on file, Abbott Diabetes Care, Inc. Data based on the number of users worldwide for FreeStyle Libre family of personal CGMs compared to the number of users for other leading personal CGM brands and based on CGM sales dollars compared to other leading personal CGM brands.
2. Data on file, Abbott Diabetes Care, Inc.
3. Hilliard, M., et al. Diabetes Technology & Therapeutics. (2019). https:/doi.org/10.1089/dia.2019.0142.
4. Haak, T. Diabetes Therapy (2017). https://doi.org/10.1007/s13300-016-0223-6.
5. Alva, S. J Diabetes Sci Technol (2020): https://doi.org/10.1177%2F1932296820958754.
6. The views, opinions, and positions expressed by FreeStyle Libre systems users are theirs alone, and do not necessarily reflect the views, opinions, and positions of Abbott or any employee thereof. The views expressed should not be used for medical diagnosis or treatment or as a substitute for professional medical advice. Individual symptoms, situations and circumstances may vary.
7. Fokkert, M. BMJ Open Diab Res Care (2019). https://doi.org/10.1136/bmjdrc-2019-000809.
8. 60-minute warm-up required when applying the sensor.
9. Sensor is water resistant in up to 1 meter (3 feet) of water. Do not immerse longer than 30 minutes.
10. Finger pricks are required if glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first twelve hours.
11. Among patient-applied sensors.
12. The FreeStyle LibreLink app is only compatible with certain mobile devices and operating systems. Please check the website for more information about device compatibility before using the app. Use of FreeStyle LibreLink requires registration with LibreView.
13. The FreeStyle Libre system apps are only compatible with certain mobile devices and operating systems. Please check the Support section of our website for more information about device compatibility before using the app. Use of the FreeStyle Libre system apps may require registration with LibreView.
14. FreeStyle Libre 2 systems are part of the same family of products.
15. Data on file, Abbott Diabetes Care, Inc. Based on the reading frequency in Dexcom G7 CGM User Guide and Medtronic Guardian Connect System User Guide compared to readings every minute for FreeStyle Libre 2 sensors.
16. Huang, E. Diabetes (2022). https://doi.org/10.2337/db22-73-LB.
17. Unger, J. Postgraduate Medicine (2020). https://doi.org/10.1080/00325481.2020.1744393.
18. Notifications will only be received when alarms settings are enabled and turned on and the sensor is within 6 meters or unobstructed of the reading device.
19. All data transferred to LibreView is encrypted using industry-standard SSL/TLS to ensure that it remains private from malicious parties.
20. Campbell, F. M. Pediatric Diabetes (2018). https://doi.org/10.1111/pedi.12735.
21. The LibreLinkUp app is only compatible with certain mobile devices and operating systems. Please check www.librelinkup.com for more information about device compatibility before using the app. Use of the LibreLinkUp app requires registration with LibreView. Dosing decisions should not be made based on this device. The user should follow instructions on the continuous glucose monitoring system. This device is not intended to replace self-monitoring practices as advised by a physician.
23. Data on file, Abbott Diabetes Care, Inc. Based on the signal strength in Dexcom G6 CGM User Guide and Medtronic Guardian Connect System User Guide.
24. The LibreView data management software is intended for use by both patients and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical glucose meter data to support effective diabetes management. The LibreView software is not intended to provide treatment decisions or to be used as a substitute for professional healthcare advice.
25. The user’s device must have internet connectivity for glucose data to automatically upload to LibreView.
26. The user’s device must have internet connectivity for glucose data to automatically upload to LibreView and to transfer to connected LibreLinkUp app users.
27. Evans, M. Diabetes Therapy (2022). https://doi.org/10.1007/s13300-022-01253-9.
28. Bolinder, J. The Lancet (2016). https://doi.org/10.1016/S0140-6736(16)31535-5.
30. FreeStyle Libre 2 User's Manual/Data on file, Abbott Diabetes Care. Inc.
34. The FreeStyle Libre 2 app is only compatible with certain mobile devices and operating systems. Please check our compatibility guide for more information about device compatibility before using the app. Use of the FreeStyle Libre 2 app requires registration with LibreView.
38. Yaron, M. Diabetes Care (2019): https://doi.org/10.2337/dc18-0166.
39. Leelarathna, L. New England Journal of Medicine (2022). https://doi.org/10.1056/nejmoa2205650.
40. Leading manufacturers include Accu-Chek, OneTouch and Ascencia.
41. Do not use during xylose absorption testing. Study conducted in 2009. Data on file, Abbott Diabetes Care Inc.
43. The FreeStyle Libre 2 app and the FreeStyle Libre 2 reader have similar, but not identical features. Fingersticks are required for treatment decisions when you see the Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectation.
45. Participating pharmacies are subject to change without notice. Product availability may vary by retailer.
46. Glucose alarms will transfer to the LibreLinkUp app users when users are connected and alarms are enabled on FreeStyle Libre systems apps.
47. The FreeStyle Libre systems apps are designed to facilitate data sharing between patients and their healthcare providers and caregivers.
48. All data transferred to LibreLinkUp is encrypted using industry-standard SSL/TLS to ensure that it remains private from malicious parties.
201. Data based on the number of users worldwide for FreeStyle Libre family of personal CGMs compared to the number of users for other leading personal CGM brands and based on CGM sales dollars compared to other leading personal CGM brands.
202. Cengiz, Eda, and William V Tamborlane. “A Tale of Two Compartments: Interstitial Versus Blood Glucose Monitoring.” Diabetes Technology & Therapeutics 11, Suppl 1 (June 2009): S11-6.
https://doi.org/10.1089/dia.2009.0002.
Stay Connected